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Objectives The aim of this prospective, randomized trial was to assess the 10-year long-term safety
and effectiveness of percutaneous coronary intervention (PCI) and minimally invasive direct coronary
artery bypass surgery (MIDCAB) for the treatment of proximal left anterior descending (LAD) lesions.
Background Long-term follow-up data comparing PCI and MIDCAB surgery for isolated proximal
LAD lesions are sparse.
Methods Patients with signiﬁcant isolated proximal LAD stenoses were randomized either to PCI
with bare-metal stents (n  110) or MIDCAB (n  110). At 10 years, data were obtained with re-
spect to the primary endpoint (death, myocardial infarction, target vessel revascularization). Angina
was assessed by the Canadian Cardiovascular Society classiﬁcation.
Results Follow-up was conducted for 212 patients at a median time of 10.3 years. There were no
signiﬁcant differences in the binary primary composite endpoint (47% vs. 36%; p  0.12) and hard
endpoints (death and infarction) between PCI and MIDCAB. However, a higher target vessel revascu-
larization rate in the PCI group (34% vs. 11%; p  0.01) was observed. Clinical symptoms improved
signiﬁcantly from baseline and were similar between both treatment groups.
Conclusions At 10-year follow-up, PCI and MIDCAB in isolated proximal LAD lesions yielded similar
long-term outcomes regarding the primary composite clinical endpoint. Target vessel revasculariza-
tion was more frequent in the PCI group. (J Am Coll Cardiol Intv 2013;6:20–6) © 2013 by the
American College of Cardiology Foundation
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21Previous trials have demonstrated that clinical prognosis in
patients with untreated high-grade proximal stenosis of the
left anterior descending (LAD) artery is poor due to the
large territory of myocardium at risk (1,2).
See page 27
Established treatment options are conventional bypass
grafting, minimally invasive direct coronary artery bypass
(MIDCAB) surgery, and percutaneous coronary interven-
tion (PCI) either with bare-metal stents (BMS) or drug-
eluting stents (DES) (3–6). In randomized trials (using
BMS) and a meta-analysis comparing stenting versus MID-
CAB, a significantly higher reintervention rate after PCI
and similar results for mortality and myocardial infarction at
6-month follow-up have been demonstrated (4,7,8). At
5-year follow-up, these results were confirmed (9).
To further elucidate advantages or disadvantages of PCI
against MIDCAB in the long term, we report the 10-year
follow-up of the largest randomized, prospective trial com-
paring MIDCAB surgery with PCI using BMS for treat-
ment of patients with isolated lesions of the proximal LAD.
Methods
The detailed design of this trial has been described previously
(4). In summary, patients with isolated high-grade lesions
75% diameter stenosis on visual assessment, no total occlu-
ion, no bifurcation lesion of the left main and the first
iagonal branch) of the proximal LAD were included. A
ardiac surgeon and a cardiologist had to find a consensus
n patient eligibility. Balanced randomization was per-
ormed after written informed consent and patients were
ssigned to stenting or surgery.
Exclusion criteria were acute coronary syndromes, addi-
ional significant coronary lesions, significant valvular heart
isease, and previous interventional or surgical treatment for
oronary artery disease. The study was approved by the
nstitutional Ethics Committee.
Stenting procedure. Stenting with BMS was performed
ccording to standard practice (4). Patients received aspirin
00 mg/day indefinitely and ticlopidine or clopidogrel for 4
eeks (following a loading dose the day before the
rocedure).
Minimally invasive direct coronary artery bypass surgery.
MIDCAB surgery was performed through a left anterolat-
eral minithoracotomy on the beating heart without cardio-
pulmonary bypass (4). The left internal thoracic artery was
used as bypass graft. Aspirin (100 mg/day) treatment was
recommended indefinitely.
Follow-up. Data were collected by a structured patient
interview at 5 years—results have been published previously
(9)—and again 10 years after randomization. Reported
clinical events were confirmed by contact with the general fpractitioner, referring cardiologist, and/or the treating hos-
pital. Death was defined as death from any cause. Death was
regarded as cardiac in origin unless obvious noncardiac
causes could be identified. In case of any doubt, death was
counted as cardiac. For in-hospital periprocedural myocar-
dial infarction, the previously chosen definition was used
with increase of the creatine kinase-myocardial band (CK-
MB) value 3 the normal value or if the ratio of CK-MB
to total CK exceeded 0.1 (4). At follow-up, the standard
universal definitions of myocardial infarction criteria were
applied (10).
Any new revascularization by either PCI or bypass
grafting was further divided into target lesion revasculariza-
tion, target vessel revascularization (TVR), and nontarget
vessel revascularization categories. For stent thrombosis
definition, the Academic Research Consortium criteria were
applied (11).
The initial study protocol at
6-month follow-up mandated a
complete clinical work-up, in-
cluding symptom-limited exer-
cise stress test and coronary an-
giography. For asymptomatic
patients, no further scheduled
routine noninvasive or invasive
studies were performed at long-
term follow-up. Repeated inter-
ventions were clinically driven
and performed in case of recur-
rence of angina and/or a positive
stress test. Quantitative angiog-
raphy was not performed in
these patients, except for the
mandatory initial 6-month an-
giography. The choice of all re-
current revascularization proce-
dures was left to the discretion of
the investigator.
All events were adjudicated by an event monitoring
committee consisting of an experienced cardiologist and
cardiovascular surgeon.
Endpoints. The primary composite endpoint was freedom
rom major adverse cardiac events (MACE), defined as
eath from any cause, myocardial infarction, and the need
or repeated TVR. Secondary endpoints were each individ-
al component of the primary endpoint. For the combined
ACE rate, to avoid double counting of patients with more
han 1 event, each patient contributed only once to the
omposite MACE endpoint and the first occurring event
as counted regardless of severity. The clinical status was
ssessed by the Canadian Cardiovascular Society’s classifi-
ation, and the need for antianginal drugs at 10-year
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
HR  hazard ratio
IQR  interquartile range
LAD  left anterior
descending
MACE  major adverse
cardiac events
MIDCAB  minimally
invasive direct coronary
artery bypass
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationollow-up was documented.
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22Statistical analysis. The initial sample size chosen to achieve
5% statistical power with a type I error of 5% by use of
-sided Fisher exact test was based on the assumption that
0% of the patients treated by stenting with BMS and 9%
reated by MIDCAB surgery would reach the combined
rimary endpoint. Accounting for losses to follow-up, 10
ore patients in each group were included, resulting in 220
andomized patients. All analyses were performed according
o the intention-to-treat principle. Patients lost to follow-up
ere included in the analysis until their last known status.
ontinuous parameters were described as mean  SD or as
edian (interquartile range [IQR]) if not normally distrib-
ted. Categorical variables were expressed as number and
ercentage of patients. Differences between the treatment
roups were assessed by Fisher exact test or the chi-square
est for categorical variables with nominal scales. For con-
inuous data with normal distribution, unpaired Student t
est was used.
Additionally, exploratory landmark analyses using the
aplan-Meier method were performed for the primary
omposite endpoint, myocardial infarction, and TVR. The
andmark was chosen at 7 months; therefore, the first
nalysis covers the period from 0 to 7 months and the
econd the period from 7 months to 10 years. The rationale
or choosing the 7-month landmark was that it became
vident that most TVR events in the PCI group occurred
arly during the first months of follow-up. Any patient with
n event before the 7-month landmark was excluded from
urther analysis for the second period regarding the com-
osite endpoint. For the TVR landmark analysis, those
atients with prior TVR or death were excluded.
The statistical analyses were conducted using SPSS (version
7.0, SPSS Inc., Chicago, Illinois). A 2-tailed p value 0.05
MIDCAB (n=110)BMS (n=110)
220 patients randomized
3 lost 10-year follow-up 5 lost 10-year follow-up
Median follow-up time 10.3 years (IQR 
9.4;11.4)
Coronary angiography at 6 months
follow-up
Figure 1. Trial Profile
BMS  bare-metal stent(s); IQR  interquartile range; MIDCAB  minimally
invasive direct coronary artery bypass surgery.as considered statistically significant.esults
Between June 1997 and June 2001, 220 consecutive patients
with isolated proximal LAD stenosis were randomized to
either surgery (n  110) or stenting (n  110). Initially,
1% of patients had type B2 or C lesions and the percentage
iameter stenosis was 82.8 7.8%. All patients received the
assigned treatment. The 10-year long-term follow-up was
completed for 212 patients (96%). Despite intensive effort,
long-term follow-up information could not be obtained for
8 patients. For survival analysis, data until their last known
status were used; median follow-up time was 10.3 years
(IQR: 9.4 to 11.4 years) (Fig. 1).
Baseline characteristics were not significantly different
between the treatment groups and have been published
previously (4).
Primary composite endpoint. In the binary event analysis at
0 years, there was no significant difference in the incidence
f the combined primary endpoint in PCI versus MIDCAB
relative risk: 0.81, 95% confidence interval [CI]: 0.62 to
.05; p  0.12) (Table 1). However, when a time-to-event
nalysis was used, the difference in event rates was statisti-
ally significant (hazard ratio [HR]: 0.65, 95% CI: 0.43 to
.98; p  0.04) (Fig. 2A).
Landmark analysis showed that this difference was mainly
riven by a higher event rate in the PCI group in the first
onths (period 0 to 7 months: HR: 0.31, 95% CI: 0.17 to
.57; p  0.01) (Fig. 2B). In contrast, for the period from
7 months to 10 years, the difference between the event
curves was no longer statistically significant (HR: 1.29, 95%
CI: 0.71 to 2.3; p  0.40) (Fig. 2C).
The binary incidence of each individual endpoint at
10-year follow-up is shown in Table 1.
Secondary endpoints. REVASCULARIZATION. In the PCI
group, the need for TVR was significantly higher compared
with that of the MIDCAB group at 10 years (34% vs. 11%,
p  0.01) (Table 1). This was also true when a time-to-
vent method of analysis was used (Fig. 3A).
Landmark analysis revealed that this difference was
argely caused by a higher TVR rate in the first analysis
Table 1. MACE at Long-Term Follow-Up (10 Years)
Stenting
(n  107)
MIDCAB
(n  105) p Value
Relative Risk
(95% CI)
Death 25 (23) 24 (23) 1.00 0.98 (0.51–1.35)
Cardiac death 9 (8) 10 (10) 0.81 1.07 (0.65–1.75)
Myocardial infarction 5 (5) 12 (11) 0.08 1.78 (0.84–3.76)
Target vessel revascularization 36 (34) 11 (11) 0.001 0.56 (0.44–0.71)
Death or myocardial infarction 26 (24) 30 (29) 0.53 1.11 (0.83–1.54)
Any major adverse cardiac
event
50 (47) 38 (36) 0.12 0.81 (0.62–1.05)
Values are n (%) per clinical event category.
CI confidence interval; MACEmajor adverse cardiac events; MIDCABminimally invasivedirect coronary artery bypass.
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23period from 0 to 7 months (HR: 0.25, 95% CI: 0.13 to 0.47;
p  0.01) (Fig. 3B), whereas in the second period from 7
months to 10 years, the difference in event curves was no
longer significant (HR: 0.71, 95% CI: 0.22 to 2.23; p 
0.53) (Fig. 3C).
Some patients had multiple TVRs. The mean number of
TVR events per patient in the stenting group who had
repeated revascularization was 1.37  0.69 (26 patients had
1, 8 had 2, 1 had 3, and 1 had 4 TVRs). Overall, in the
interventional group, 49 TVRs were performed in 36
patients (30 [83%] PCIs, 4 [11%] surgical, 2 [6%] PCIs and
surgical).
In the surgical group, 8% required TVR at 6-month
follow-up; additional revascularization was necessary in 1%
at 5-year follow-up and increased by another 1% at long-
term follow-up. The mean number of TVRs per patient in
the MIDCAB group was 1.18  0.60. A total of 13 TVRs
(9 [69%] PCIs and 4 [31%] surgical) were performed in 11
patients in the surgery group (10 patients had 1 and 1
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Figure 2. Freedom From Combined Primary Study Endpoint
Kaplan-Meier curve showing freedom from major adverse cardiac events durin
10 years (C). The log-rank test was used to compare stenting and minimally in
B and C represent the 7-month landmark.patient had 3 TVRs).Proximal LAD restenosis or bypass dysfunction with a
necessity for target lesion revascularization occurred in 33
patients in the PCI group and 9 in the MIDCAB group
(30% vs. 9%, p  0.001).
Nontarget vessel revascularization procedures at 10-year
follow-up were necessary in 19 patients in the stenting
group and 12 in the MIDCAB group (17% vs. 11%, p 
0.24), reflecting the progressive nature of coronary artery
disease.
DEATH ANDMYOCARDIAL INFARCTION. All-cause mortal-
ity did not differ between the 2 treatment groups at
10-year follow-up (PCI 23% vs. MIDCAB 23%, p 
1.00) (Table 1). In addition, cardiac death rates were
similar (Table 1). The cardiac deaths in the stenting
group included 1 death from unknown cause, 2 infarc-
tions, and 6 deaths due to congestive heart failure. The 10
cardiac deaths after surgery included 2 perioperative
deaths and 1 death at follow-up from unknown cause.
Three patients died of heart failure and 4 of acute
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24The rate of myocardial infarctions was not statistically
different between stenting and surgery at 10-year follow-up
(5% vs. 11%, p  0.08). Landmark analysis showed, despite
the numerical higher event rates in the MIDCAB group, no
statistically significant differences in the 0 to 7 months
period (HR: 0.59, 95% CI: 0.14 to 2.48; p  0.49) or 7
months to 10 years period (HR: 0.29, 95% CI: 0.06 to 1.39;
p  0.10).
Except for 2 definitive stent thromboses at 6-month
follow-up, no subacute or late stent thromboses were
observed at longer follow-up in the PCI group.
ANGINAL SYMPTOMS AND ANTIANGINAL MEDICATION.
After PCI, the median Canadian Cardiovascular Society
classification score improved from 2 (IQR: 2 to 3) to 0
(IQR: 0 to 1) (p  0.01) at 10-year follow-up, and 69% of
he patients were completely free from angina. In the
urgery group, the median angina class improved from 2
IQR: 2 to 3) to 0 (IQR: 0 to 1) (p  0.01 for the
omparison with baseline), with 65% of patients free of
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Figure 3. Freedom From TVR
Kaplan-Meier curve showing freedom from target vessel revascularization (TVR
10 years (C). The log-rank test was used to compare stenting and minimally in
B and C represent the 7-month landmark.nginal symptoms (p  0.77 for the intergroup comparison).The rate of antianginal medication was not different at
0-year follow-up (20% vs. 19%, p  0.99). Use of
dditional cardiac medication was similar between the 2
reatment groups (Table 2).
P<0.01; log-rank
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Table 2. Cardiovascular Medication at Long-Term Follow-Up
Stenting
(n  81)
MIDCAB
(n  78) p Value
Beta-blocker 60 (74) 59 (75) 0.85
ACE inhibitor/AT-1 antagonist 59 (73) 55 (71) 0.86
Statin 55 (68) 53 (68) 0.99
Aspirin 60 (74) 54 (69) 0.59
Thienopyridines 8 (10) 7 (9) 0.99
Nitrates 16 (20) 15 (19) 0.99
Calcium antagonists 18 (22) 12 (15) 0.31
Antidiabetic medication 17 (21) 14 (18) 0.84
Values are n (%) per clinical event category.
ACE angiotensin-converting enzyme; AT-1 angiotensin-1; MIDCABminimally invasiveB
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25Discussion
To the best of our knowledge, this prospective, randomized
study is the first to compare long-term results at 10 years in
patients with isolated lesions of the proximal LAD treated by
either PCI with BMS or MIDCAB surgery. No significant
differences in the composite endpoint and individual “hard”
endpoints, such as death and myocardial infarction, could be
found between both treatment groups. However, consistent
with short- and midterm follow-up results, there was a signif-
icantly lower TVR rate in favor of the surgery group. In the
time frame of the landmark analysis from 7 months to 10 years,
no significant differences in the primary composite endpoint
and secondary endpoints could be observed.
Several clinical trials have demonstrated an initial higher
complication rate in cardiac surgery due to perioperative risk,
which at 6-month follow-up is offset by the stenting group due
to the higher rate of TVR (7,8). At longer follow-up, the
MACE rates align, which is reflected in Figure 2. Notably, the
higher TVR rate in the stenting group was primarily driven
during the first 6 months, as demonstrated in Figure 3. An
important reason for the higher TVR rate in the PCI group
might have been the use of BMS and the mandatory follow-up
angiography at 6 months. Routine angiographic follow-up
leads to additional revascularizations in comparison with sole
clinical follow-up (12,13).
Previous studies have shown restenosis rates up to 50%
(7,8) in proximal LAD stenoses, and proximal LAD lesion
location has been identified as a risk factor for restenosis
after BMS implantation (14). Since the introduction of
DES, restenosis rates have been dramatically reduced in
comparison with BMS for all lesion subsets in short- (15) as
well as midterm follow-up (6,16). Importantly, with DES,
the proximal LAD lesion location is no longer an isolated
risk factor for restenosis (5,17,18). Moreover, second-
generation DES seem to reduce the risk of in-stent reste-
nosis at any location even further in comparison with
first-generation DES, with target lesion revascularization
rates ranging from only 2.2% to 3.1% versus 4.6% to 5.5%
(16,19). MACE rates might also be lower by using second-
generation compared with first-generation DES (5% to 6%
vs. 9%) (16,19) as well as mortality at 2-year follow-up (16).
Thus, the use of DES might close the gap in repeat
revascularization compared with MIDCAB for significant
proximal LAD disease. Of note, in the present study, there
was a high prevalence of type B2 and C lesions, which are
well known for their higher in-stent restenosis rates in
comparison with type A and B1 lesions (20,21).
It should also be noted that the present study was
performed with earlier generations of coronary artery stabi-
lization devices for MIDCAB surgery and reflects early
experience with this technique. We have previously dem-
onstrated that a learning curve for MIDCAB surgery exists,
with fewer complications occurring with increasing operatorexperience (22). Therefore, TVR rates may be lower for
both PCI and MIDCAB in a more contemporary setting.
The effect of PCI with DES versus MIDCAB surgery in
proximal LAD lesions has been evaluated in only 1 ran-
domized clinical trial showing noninferiority of DES in
comparison with MIDCAB surgery at 12-month follow-up
(5). However, the value of each treatment option needs to
be further clarified in future randomized trials with longer
follow-up.
The lack of a significant difference in mortality or myocar-
dial infarction rates between PCI and surgery observed in the
present study is in line with other trials in patients with isolated
proximal LAD coronary artery lesions (23,24).
Relief of angina was preserved at 10-year long-term
follow-up. In the PCI group, 69% of the patients were free
from angina, and in the MIDCAB group, 65% were also
free of angina. Similar results have been published for
proximal LAD lesions in other trials ranging from 61% to
94% for PCI and also for surgery (24–26).
Several studies have demonstrated the long-term patency
of internal mammary arterial grafting and its superiority
compared with vein grafts anastomosed to the LAD in
terms of survival, freedom from infarction, angina, and
repeated revascularization (22,27). There is evidence that
the duration of benefit extends for 10 years; therefore,
long-term follow-up of revascularization trials is essential to
further evaluate the magnitude of benefit over time (27,28).
Study limitations. Some limitations of the present trial need
ttention. First, some events might have been missed due to
patients being lost to long-term 10-year follow-up. Also,
esults are from a single high-volume tertiary care center
nd may not be generalizable. Due to the trial design,
linding was not possible. Finally, both PCI and MIDCAB
echniques have improved over time, and DES use is the
urrent gold standard in patients undergoing PCI of the
roximal LAD. Therefore, the results of this long-term
nalysis may not be applicable to current best practice.
onclusions
At the 10-year follow-up, stenting with BMS or MIDCAB
for isolated proximal LAD lesions was associated with
similar long-term outcomes regarding hard endpoints
(death and infarction) and the combined composite end-
point at the cost of a higher TVR rate in the PCI group
mainly within the first 6 months.
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